Glutide for Ending Methamphetamine (GEM) Study
This study, called GEM, is looking at whether a medication called Semaglutide (also known as Wegovy) can help treat methamphetamine use disorder. It's a two-part study. The first part is a small pilot study with 25 participants to see if Semaglutide is practical and acceptable, and if it shows early signs of working. The second part will be a larger study with 162 participants, comparing Semaglutide to a placebo (a sugar pill) to see how well it works. We'll be looking at things like how many people join the study, if they take their medication as planned, and changes in methamphetamine use after 12 weeks. You can join if you are between 18 and 65 years old and meet other study requirements. The current status of the study is unclear.
- Study design
- This study has two phases. The first is a small, open-label pilot study with 25 participants. The second is a larger, randomized-controlled trial with 162 participants, where some will receive Semaglutide and others a placebo, and neither you nor the researchers will know which you are receiving (blinded).
- What's involved
- If you join the pilot study, you will receive Wegovy for 12 weeks, with a follow-up visit at week 20. The second phase will be similar, but with randomization to Wegovy or placebo.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants in the pilot study will have a follow-up visit at week 20. The study will measure outcomes up to 20 months after the start of the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Glutide for Ending Methamphetamine
At a glance
Conditions
NCT07204249
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Center on Substance Use and Health
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Ratio of eligible to enrolled participants14 months
Feasibility of Wegovy for MeUD treatment: Feasibility will be determined by measuring the ratio of eligible to enrolled participants
- Proportion of on-time injections20 months
Acceptability of Wegovy for MeUD treatment: Acceptibility of the treatment will be determined by measuring the adherence to available study drug injections (proportion of on-time injections administered)
- Past month methamphetamine use at baseline vs. week 1212 weeks
Reduced methamphetamine use: Signs of reduced methamphetamine use by hair testing or self-report (timeline follow back) for the past four weeks, measured at baseline vs. week 12.
- Rate of study-drug discontinuation12 weeks
Safety of Wegovy for MeUD treatment: Safety will be determined by measuring the rate of study-drug discontinuation due to adverse events
- Reduced methamphetamine use12 weeks
Reduced methamphetamine use, measured by proportion achieving "response," defined as 3 out of the final 4 urines collected negative for methamphetamine.